Patent ID: 7244733

Claim:
A method for treating breast cancer, comprising administering to a warm-blooded species in need thereof, a therapeutically effective amount of a compound of formula I: its enantiomer, diastereomer, or pharmaceutically acceptable salts thereof, wherein X and Y are independently O, OCO, S, SO SO 2 , CO, CO 2 , NR 10 , NR 11 CO, NR 12 CONR 13 , NR 14 CO 2 , NR 15 SO 2 , NR 16 SO 2 NR 17 , SO 2 NR 18 , CONR 19 , halogen, nitro, cyano, or X or Y are absent; Z is O, S, N, or CR 20 ; R 1 is hydrogen, CH 3 , OH, OCH 3 , SH, SCH 3 , OCOR 21 , SOR 22 , SO 2 R 23 , SO 2 NR 24 R 25 , CO 2 R 26 , CONR 27 R 28 , NH 2 , NR 29 SO 2 NR 30 R 31 , NR 32 SO 2 R 33 , NR 34 COR 35 , NR 36 CO 2 R 37 , NR 38 CONR 39 R 40 , halogen, nitro, or cyano; R 2 and R 3 are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl or substituted heterocycloalkyl, or when X is halo, nitro or cyano R 2 is absent or when Y is halo, nitro or cyano R 3 is absent; R 4 is alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl; R 5 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, or substituted aralkyl; or R 4 and R 5 may together form an optionally substituted monocyclic 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, or an optionally substituted bicyclic 7-11 membered saturated or unsaturated heterocyclic ring, except that when Z is O or S, R 5 is absent; R 6 is hydrogen, alkyl, substituted alkyl, substituted aryl, heterocyclo, substituted heterocyclo, NR 7 R 8 , OR 9 or halogen; R 7 is selected from the group consisting of hydrogen, C 2 -C 20 alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo, R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 21 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 34 , R 35 , R 36 , R 38 , R 39 and R 40 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo, R 22 , R 23 , R 33 and R 37 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, and substituted heterocyclo; and R 20 is selected from the group consisting of hydrogen, lower alkyl and substituted alkyl, or R 20 is absent if the carbon to which it is attached is part of an unsaturated aryl or heteroaryl ring; with the provisos that: a. R 2 is not hydrogen if X is SO, SO 2 , NR 14 CO 2 , or NR 15 SO 2 , b. R 3 is not hydrogen if Y is SO, SO 2 , NR 14 CO 2 , or NR 15 SO 2 and a pharmaceutically acceptable carrier.